Febrile neutropenia and myelosupression is one of the serious adverse effect or the toxic effect of most anti-cancer drugs. When these drugs are prescribed, myelosupression is seen by which pancytopenia (where all blood cells are decreased) is seen. Granulocyte colony stimulating factors are given in order to regain the cell counts. In this case report we discuss about the patient who has diagnosed with carcinoma of larynx experienced the pancytopenia and how he was managed.

Background: Febrile neutropenia is one of the most serious complications of the cancer chemotherapy drugs. Febrile neutropenia is a life threatening condition where the neutrophil count gets lowered which leads to enhance some of the factors associated with morbidity, mortality and financial costs of the patients which are associated with supportive care. The colony stimulating factor is helpful in preventing the adverse effects of anti-cancer drugs such as neutropenia who receives the chemotherapy both in curative patients and palliative care patients.

Keywords: Febrile neutropenia, colony stimulating factors, filgrastim, myelosupression, meropenum.

1. Viscoli C, Varnier O, Machetti M (2005) Infections in patients with febrile neutropenia : epidemiology, microbiology, and risk stratification. Clin Infect Dis 40 (suppl 4): 240-245
2. Lustberg MB (2012) Management of Neutropenia in cancer patients. Clin Adv Hematol Oncol 10 (12):825-826
3. Farrow CA, Hicks AB, Kamen AB. Essentials of Pediatric Intensive Care. Oncology. 2ª ed. San Francisco: Churchill-Livingstone; 1997.
4. Aapro, M., Crawford, J., & Kamioner, D. (2010). Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Supportive Care in Cancer, 18(5), 529–541. http://doi.org/10.1007/s00520-010-0816-y

B. Sunil Kumar Nayak

Interns, Department of Clinical Pharmacy, Vaageswari College of Pharmacy, Karimnagar, Telangana state, India